Another case of preventable death from asthma.

INTRODUCTION: Asthma prevalence is 262 million globally, with more than 1,000 deaths each day, most of them preventable. We were performing a longitudinal study, in Brazil, with the objective to following up patients who had a severe asthma attack and attended an emergency room (ATTACK Study). Here we present a case of a 28-year-old woman presenting what was considered moderate asthma, enrolled in ATTACK, who subsequently died of asthma. CASE STUDY: The patient was initially evaluated at an emergency room (ER) with uncontrolled asthma and no regular treatment. She had an asthma diagnosis just before this visit to the ER, despite presenting symptoms of asthma since childhood. She was subsequently evaluated by a specialist, who prescribed a treatment with regular inhaled corticosteroid and an inhaled bronchodilator, if necessary. The patient was systematically monitored by telephone for six months. RESULTS: The patient did not adhere to the treatment, in spite of repeated warnings, and 6 months later had an asthma attack resulting in her death. CONCLUSION: It is important to prioritize asthma in primary health care, including building capacity health care professionals for early diagnosis, asthma management, and to educate patients with asthma patients for the identification of worsening and signs of severity, to manage the exacerbations according to a written asthma plan. This may reduce the number of premature and preventable asthma deaths.

Citologia do escarro induzido em asmáticos infectados pelo Schistosoma mansoni / Induced sputum cytology in asthmatics infected with Schistosoma mansoni

A infecção pelo Schistosoma mansoni inibe manifestação da asma. A avaliação do escarro induzido em pacientes infectados pelo parasita pode trazer informações importantes sobre a relação entre doenças alérgicas e parasitoses. Objetivo: Avaliar a celularidade do escarro em asmáticos em uma área endêmica em esquistossomose na Bahia. Métodos: Estudo randomizado, duplo cego, controlado com placebo, incluindo asmáticos infectados pelo S. mansoni e um grupo de asmáticos não infectados. Foi utilizada a celularidade do escarro induzido, em contagens sequenciais pré (D0) e pós-tratamento (D7, D60 e D90), para avaliar os efeitos do tratamento da parasitose com praziquantel sobre a asma. Resultados: Avaliados 22 indivíduos asmáticos infectados pelo S. mansoni e grupo controle adicional composto por oito asmáticos não infectados. O grupo que usou praziquantel não diferiu do grupo placebo quando comparada a celularidade do escarro. Houve aumento no número de eosinófilos nos D7, D60 e D90 no grupo placebo, quando comparados ao basal, e no D60 no grupo praziquantel. O número total de células aumentou em relação ao basal no D7 e no D90 para o grupo placebo, e no D90 para o grupo praziquantel. O grupo que usou praziquantel apresentou uma redução do volume expiratório forçado no 1º segundo (VEF1) no D7, D60 e D90. Não houve associação entre a eosinofilia e a gravidade da asma. Conclusão: No presente estudo não foi encontrada correlação entre os tipos celulares encontrados e a gravidade da asma, nem houve variação significativa do percentualde eosinófilos em resposta ao tratamento da esquistossomose...

Schistosoma mansoni infection inhibits asthma symptoms. Assessment of induced sputum in infected patients may shed light on the relationship between allergic diseases and parasite infections. Objective: To assess the cellularity of induced sputum in asthmatic patients living in an endemic area of schistosomiasis in the Brazilian state Bahia. Methods: This randomized, double blind, placebo-controlled study included asthmatic patients infected with S. mansoni and a group of non-infected asthmatics (controls). Cellularity of induced sputum was analyzed based on cell counts before (D0) and after treatment (D7, D60, and D90), to evaluate the effects of treatment with praziquantel on asthma. Results: A total of 22 asthmatics infected with S. mansoni and 8 controls were assessed. Induced sputum cellularity in the group treated with praziquantel did not differ from that of the group treated with placebo. However, compared to baseline counts, a higher number of eosinophils was found in the placebo group on D7, D60, and D90, and on D60 in the treatment group. Total cell counts increased from baseline to D7 and D90 in the placebo group, and from baseline to D90 in the treatment group. Moreover, the treatment group showed a reduction in forced expiratory volume in 1 second (FEV1) on D7, D60, and D90. There was no association between eosinophilia and asthma severity. Conclusion: In the present study, there was no correlation between asthma severity and the cell types found during cellularity assessment, nor was there an association between treatment of schistosomiasis and sputum eosinophilia...

The effect of antihelminthic treatment on subjects with asthma from an endemic area of schistosomiasis: a randomized, double-blinded, and placebo-controlled trial.

This is a prospective, double-blinded, and placebo-controlled trial evaluating the influence of antihelminthic treatments on asthma severity in individuals living in an endemic area of schistosomiasis. Patients from group 1 received placebo of Albendazole or of Praziquantel and from group 2 received Albendazole and Praziquantel. Asthma severity was assessed by clinical scores and by pulmonary function test. There was no significant difference in the asthma scores from D0 to D1-D7 after Albendazole or Praziquantel and from D0 to D30-90 after Albendazole or Praziquantel in both, group 1 and 2. It was observed, however, a clinical worsening of the overall studied population after 6 months and 12 months of antihelminthic treatments. Additionally, we observed increased frequency of forced expiratory volume in 1 second (FEV1) <80% on 12 and 18 months after treatment. The worsening of asthma severity after repeated antihelminthic treatments is consistent with the hypothesis of the protective role conferred by helminths in atopic diseases.